Effects of nintedanib on the microvascular architecture in a lung fibrosis model
- 1.5k Downloads
Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis, has anti-fibrotic, anti-inflammatory, and anti-angiogenic activity. We explored the impact of nintedanib on microvascular architecture in a pulmonary fibrosis model. Lung fibrosis was induced in C57Bl/6 mice by intratracheal bleomycin (0.5 mg/kg). Nintedanib was started after the onset of lung pathology (50 mg/kg twice daily, orally). Micro-computed tomography was performed via volumetric assessment. Static lung compliance and forced vital capacity were determined by invasive measurements. Mice were subjected to bronchoalveolar lavage and histologic analyses, or perfused with a casting resin. Microvascular corrosion casts were imaged by scanning electron microscopy and synchrotron radiation tomographic microscopy, and quantified morphometrically. Bleomycin administration resulted in a significant increase in higher-density areas in the lungs detected by micro-computed tomography, which was significantly attenuated by nintedanib. Nintedanib significantly reduced lung fibrosis and vascular proliferation, normalized the distorted microvascular architecture, and was associated with a trend toward improvement in lung function and inflammation. Nintedanib resulted in a prominent improvement in pulmonary microvascular architecture, which outperformed the effect of nintedanib on lung function and inflammation. These findings uncover a potential new mode of action of nintedanib that may contribute to its efficacy in idiopathic pulmonary fibrosis.
KeywordsIdiopathic pulmonary fibrosis Angiogenesis inhibitors Intussusceptive angiogenesis Microvascular corrosion casting Synchrotron radiation tomographic microscopy
This work is dedicated to the memory of the late Prof. Moritz A. Konerding. The authors acknowledge the skillful technical assistance of Kerstin Bahr (University Medical Center Mainz), Janine Beier, Helene Lichius, and Andrea Vögtle (all Boehringer Ingelheim, Biberach). Editorial assistance, funded by Boehringer Ingelheim, was provided by Clare Ryles of Fleishman-Hillard Fishburn. M.A., L.W., M.A.K., D.Sc., and S.J.M were involved in the conception and design. M.A., Y.O.K., W.L.W., C.D.V., S.K., D.St., and L.W. were involved in the experimental work, analysis, and interpretation. M.A., Y.O.K., W.L.W, C.D.V., D.Sc., S.J.M., S.K., D.St., and L.W. drafted the manuscript and revised it for intellectual content. M.A. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
This study was funded in part by Boehringer Ingelheim, Biberach, Germany
- 1.Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782CrossRefPubMedGoogle Scholar
- 7.Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, Roth M (2014) Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 15:157CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Artaechevarria X, Blanco D, Pérez-Martín D, de Biurrun G, Montuenga LM, de Torres JP, Zulueta JJ, Bastarrika G, Muñoz-Barrutia A, Ortiz-de-Solorzano C (2010) Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT. Eur Radiol 20:2600–2608CrossRefPubMedGoogle Scholar
- 15.Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR (2014) INPULSIS Trial Investigators: efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082CrossRefPubMedGoogle Scholar
- 35.de García de Alba C, Buendia-Roldán I, Salgado A, Becerril C, Ramírez R, González Y, Checa M, Navarro C, Ruiz V, Pardo A, Selman M (2015) Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J Respir Crit Care Med 191:427–436CrossRefPubMedGoogle Scholar